[20] found truncated STMN-2 to be a highly specific biomarker for FTLD-TDP, as STMN-2 was absent in brain tissues of patients with FTLD-FUS, FTLD-tau and in controls, and was absent in spinal cords of patients with ALS-SOD1 and in controls. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.